Tenax Therapeutics
TENX
21 hedge funds and large institutions have $8.43M invested in Tenax Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
98% more capital invested
Capital invested by funds: $4.25M → $8.43M (+$4.17M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
11% more funds holding
Funds holding: 19 → 21 (+2)
3.91% more ownership
Funds ownership: 36.04% → 39.95% (+3.9%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$809K |
| 2 |
Morgan Stanley
New York
|
+$360K |
| 3 |
Millennium Management
New York
|
+$130K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$108K |
| 5 |
Two Sigma Investments
New York
|
+$65.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$173K |
| 2 |
VPC
Vestal Point Capital
New York
|
-$137K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$135K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$101K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$84K |
TENX Hedge Fund Activity: Q4 2024 in Review
21 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q4 2024, worth a combined $8.43M — up 98% from $4.25M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TENX positions and 5 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $809K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $173K sold.
- 21 institutional investors held Tenax Therapeutics (TENX) as of Q4 2024, up from 19 in Q3 2024.
- Funds reported $8.43M of Tenax Therapeutics stock for Q4 2024, up 98% quarter-over-quarter.
- 7 funds opened new Tenax Therapeutics positions in Q4 2024 and 5 closed out, a net change of +2 holders.
- The largest Tenax Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $809K added.
- The largest Tenax Therapeutics seller in Q4 2024 was Stonepine Capital Management, an estimated $173K sold.
Based on aggregated 13F filings for Q4 2024.